StonvexLoading…
StonvexStonvexStonvexCore line items from JNJ's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-14 | Q1 2026 2026-03-29 | Annual 2025 2025-12-28 | Q3 2025 2025-09-28 | Q2 2025 2025-06-29 |
|---|---|---|---|---|---|
Revenue | $25.27B | $24.06B | $94.19B | $69.63B | $45.64B |
Operating Income | Not available | $5.99B | $32.58B | $27.61B | $20.12B |
Net Income | Not available | $5.24B | $26.80B | $21.69B | $16.54B |
EPS (Diluted) | $2.87 | $2.14 | $11.03 | $8.94 | $6.82 |
Total Assets | Not available | $200.89B | $199.21B | $192.82B | $193.39B |
Total Liabilities | Not available | $119.71B | $117.67B | $113.54B | $114.92B |
Cash & Equivalents | Not available | $21.69B | $19.71B | $18.23B | $18.58B |
Free Cash Flow OCF − CapEx | Not available | $1.47B | $19.70B | $14.23B | $6.21B |
Shares Outstanding | Not available | 2.45B | 2.43B | 2.42B | 2.42B |